Objectives: Diastolic dysfunction that determines symptoms and prognosis in patients with systolic dysfunction causes heart failure even in the absence of systolic dysfunction. Our recent studies have suggested that myocardial stiffening is likely to play a crucial role in triggering deleterious cardiac disorder. This study investigated differential contribution of left ventricular (LV) hypertrophy and fibrosis to myocardial stiffening in the pressure-overloaded heart. Methods: Dahl-Iwai salt-sensitive rats fed on high-salt diet since 7 weeks transit to congestive heart failure at 20 weeks following development of hypertension, LV hypertrophy and fibrosis, and 20 such rats were divided into three groups: rats treated with angiotensin II type 1 receptor antagonist from 8 weeks (n57), rats treated with calcineurin inhibitor from 8 weeks (n56), and untreated rats (n57). Results: Administration of angiotensin II type 1 receptor antagonist and calcineurin inhibitor did not affect blood pressure and allowed the development of compensatory hypertrophy. However, in contrast to the untreated rats, additive and excessive LV hypertrophy was not observed in either of the treated rats. The blockade of angiotensin II kept LV hydroxyproline content, a ratio of type I to type III collagen mRNA levels, collagen solubility and myocardial stiffness constant at the normal level; however, the calcineurin inhibition failed. Conclusions: Myocardial stiffening may be attributed to progressive collagen accumulation, collagen phenotype shift and enhanced collagen cross-linking, but not to either compensatory LV hypertrophy or LV hypertrophy that progresses from the compensatory stage.
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Introduction also determines symptoms and prognosis in patients with systolic dysfunction [4, 5] . Left ventricular (LV) diastolic dysfunction causes heart Myocardial stiffness and relaxation are the main deterfailure even without systolic dysfunction. This is called minants of ventricular diastolic function [6] . Relaxation diastolic heart failure. Several epidemiological investigaabnormality is an early sign of diastolic dysfunction in tions have confirmed that nearly half of subjects with heart cardiovascular diseases [6] , and our recent studies demonfailure in the community have diastolic heart failure [1] [2] [3] , strated that the transition from the compensated stage to and that its prognosis is poor [3] . Diastolic dysfunction overt diastolic heart failure stage is associated with progressive myocardial stiffening but not with further progression of relaxation abnormality [7, 8] . Therefore, myocardial stiffening is likely to play a crucial role in *Corresponding author. Tel.: 181-6-6879-6612; fax: 181-6-6879-triggering deleterious cardiac disorder.
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Both collagen accumulation within the myocardium and Industries Ltd, and FK506 was a gift from Fujisawa LV hypertrophy have been considered to induce myocarIndustries Ltd. dial stiffening; however, previous studies have resulted in Echo studies were carried out at 7, 13, and 20 weeks. At conflicting conclusions about their contribution [9] [10] [11] . 20 weeks, echo study was followed by a hemodynamic Our recent study reported that there are two types of study. Systolic blood pressure was measured with a tail hypertrophy in hypertensive heart [12] . LV hypertrophy cuff system (BP-98A, Softron, Tokyo, Japan). induced at the earlier stage is necessary to compensate for pressure overload, but that at the later stage is an excessive 2 .2. Echo studies and unnecessary type. The latter type is likely dependent on the activation of renin-angiotensin system. In previous Echo recordings were obtained as previously described studies, the difference in types of hypertrophy from the [15] . Specifically, rats were anesthetized with intraperiviewpoint of adaptation was not taken into account.
toneal administration of ketamine HCl (50 mg / kg) and The calcineurin transcriptional pathway as well as xylazine HCl (10 mg / kg), and were held in the half renin-angiotensin system is considered to play a key role left-lateral position. Rats were allowed to breathe spontain the development of pressure-overload hypertrophy and neously during the echo studies. A commercially available heart failure [13] , but their roles seem different [12, 14] .
echo machine equipped with a 7.5 MHz transducer The blockade of calcineurin activity and that of renin-(SONOS 2000, Hewlett-Packard, Andover, MA) was used angiotensin system prevented the excessive and unnecesto measure LV inner diameter and wall thickness at a paper sary hypertrophy, respectively. The blockade of reninspeed of 100 mm / s. LV fractional shortening and LV mass angiotensin system also prevented development of fibrosis; were calculated as previously described [15] . Our previous however, blockade of calcineurin activity did not. Thus, study demonstrated that the in vivo echo measurement of the comparison of the blockade of these pathways may LV mass well correlated with the ex vivo measurement clarify the contribution of fibrosis to myocardial stiffness. [15] . LV mass corrected for body weight was provided as This study investigated the differential contribution of LV mass index. LV mid-wall fractional shortening was LV hypertrophy and fibrosis to myocardial stiffening in the calculated with a Shimizu's model [16] to avoid the pressure-overloaded heart using pharmacological blockade over-estimation of the systolic function in hypertrophied of angiotensin II type 1 receptor and calcineurin activity.
hearts as previously described [15] . Measurement represents the mean of at least three consecutive cardiac cycles.
.3. Hemodynamic studies . Methods
Following the echo study at 20 weeks, a 1.5 F highThis study conforms to the guiding principles of Osaka fidelity manometer-tipped catheter (SPR-407, Millar InUniversity Graduate School of Medicine with regard to struments, Houston, TX) was introduced through the right animal care and to the 'Position of the American Heart carotid artery into the left ventricle after the manometer Association on Research Animal Use'.
was calibrated relative to atmospheric pressure. Tracings of LV pressure were digitized at a rate of 2000 samples / s 2 .1. Subjects with a commercially available analog to digital converter (MP100WS, BIOPAC Systems, Inc., Goleta, CA) and a Laboratory chow containing 0.3% NaCl was fed to personal computer (Power Book 550c, Apple Computer, weaning male Dahl-Iwai salt-sensitive (Dahl-S) rats (DIS / Inc., Cupertino, CA) using dedicated software (AcknowlEis, Eisai, Tokyo, Japan) until 7 weeks when diet was edge III, Version 3, BIOPAC Systems, Inc., Goleta, CA). switched to laboratory chow containing 8% NaCl. Our
The digitized LV pressure recording was used to calculate laboratory demonstrated that this is a model for diastolic the time constant of isovolumic LV pressure fall (tau) using heart failure based on hypertensive heart disease [15] . The a non-zero asymptote method as previously described [15] . diet and tap water were provided ad libitum throughout the LV end-diastolic pressure was determined as the pressure experiment. The rats were divided into three groups: rats just before the onset of an increase in LV systolic pressure with oral administration of angiotensin II type 1 receptor [17] . antagonist (candesartan cilexetil) at 1 mg / kg per day from 8 weeks (n57) [12] , rats with oral administration of 2 .4. Determination of myocardial stiffness constant calcineurin inhibitor (FK506) at 1 mg / kg per day from 8 weeks (n56) [14] , and untreated rats (n57). Candesartan
Simultaneous recordings of LV pressure and LV M-mode cilexetil and FK506 were given by gastric gavage every echogram were obtained at 20 weeks in all the rats, and morning. The male Dahl-S rats continuously fed the 0.3% myocardial stiffness constant following the method of NaCl chow were used as age-matched controls (n57).
Sugawara et al. [18, 19] was obtained as previously deCandesartan cilexetil was a gift from Takeda Chemical scribed [8] .
Specifically, LV pressure tracing and M-mode echocarmg / ml at 4 8C for 24 h with stirring. The solution was diogram were scanned into a computer system (Power centrifuged at 20 0003g for 30 min at 4 8C. Sodium Macintosh 7600 / 120, Apple Computer, Inc.), and LV chloride was added to the supernatant to a concentration of pressure, internal diameter, and wall thickness were digit-2.0 M NaCl, and the solution was stirred for 24 h at 4 8C. ized over a cardiac cycle. LV mean wall stress (s) was
The solution was centrifuged at 20 0003g for 30 min at calculated using the following equation : 4 8C, and the pellet was incubated in 0.2 M NH HCO 4 3 (pH 7.0) and 25% b-mercaptoethanol overnight at 40 8C.
The solution was dialyzed into 1% acetic acid, lyophilized, where P is LV pressure, D is LV short axis diameter and H dissolved in 0.6 ml of 70% formic acid containing 20 mg is wall thickness of the region of interest. Then, the CNBr per 100 mg original tissue for 4 h at 30 8C, and diastolic s 2 ln(1 /H ) data points were fitted to a single centrifuged at 50003g for 20 min. The supernatant was exponential curve with zero asymptote to calculate lyophilized and used for the measurement of hydroxymyocardial stiffness constant:
proline content. The ratio of hydroxyproline content in CNBr soluble fraction to the total tissue hydroxyproline
content was used as a measure of tissue collagen solubility where K was determined as myocardial stiffness constant.
and subsequently as an index of the degree of collagen The mean value of myocardial stiffness constant of the cross-linking [23] . septum and the posterior wall was used for statistical analysis.
2 .8. Statistical analysis
.5. Tissue sampling
All statistical analyses were performed using commercially available statistical software (STATVIEW version Following adequate additional anesthesia after the 4.54, Abacus Concepts). Serial data were analyzed by hemodynamic study, an incision was made in the chest and ANOVA for repeated measurements. Differences at spethe left ventricle was harvested and weighed as postcific stages among groups were assessed using one-factor mortem LV mass. The left ventricle was removed, sliced analyses of variance and Fisher's protected least significant into several pieces, weighed, immediately placed in liquid difference test. A probability value ,0.05 was considered nitrogen and stored at 280 8C. One of the pieces was used statistically significant. for the measurement of the total tissue hydroxyproline content as previously described [7] . Results were calculated as hydroxyproline content per wet weight of tissue.
. Results

.6. Quantification of mRNA levels of type I and III
.1. Untreated rats collagens
Blood pressure was elevated from 7 to 13 weeks and The expression of mRNAs for type I and III collagens remained constant thereafter (Fig. 1) . At 13 weeks, LV and GAPDH in the left ventricle was quantified with mass and LV mass index were significantly greater in the real-time quantitative PCR using Prism 7700 sequence detector (Perkin-Elmer) as previously described [7, 20] , and a ratio of type I to type III collagen mRNA levels was determined as in our and other previous studies [20, 21] .
.7. Determination of the soluble collagen after CNBr cleavage
Collagen was extracted and digested with CNBr according to the modified procedure of Iimoto et al. [22] . Briefly, frozen LV tissues (|100 mg) were homogenized at 4 8C in 1.0 ml buffer containing 0.1 mM N-ethylmaleimide, 10 mM phenylmethanesulfonyl fluoride, 1 mM EDTA and 25 mM Na HPO . Subsequently the samples were centrifuged 2 4 at 20 0003g for 30 min at 4 8C. The pellet was dissolved in the same buffer, stirred at 4 8C for 3 h, centrifuged at untreated rats than in the control rats (Fig. 2) . At 20 Mid-wall fractional shortening was not different between weeks, the untreated rats showed signs of overt heart the control and untreated rats (Table 1 ). failure such as tachypnea, labored respiration and loss of activity. LV mass and LV mass index progressively in-3 .2. Effects of blockade of angiotensin II receptor versus creased from 13 to 20 weeks (Fig. 2) . At 20 weeks, calcineurin inhibition postmortem LV mass, a ratio of postmortem LV mass to body weight, LV end-diastolic pressure and a lung to body
The pharmacological blockade of angiotensin II type 1 weight ratio were also higher in the untreated rats than in receptor or of calcineurin activity did not affect blood control rats (Table 1) . These were associated with inpressure or mid-wall fractional shortening (Fig. 1 , Table  creases in the hydroxyproline content, the ratio of type I to 1); however, none of the blockades allowed the elevation type III collagen mRNA levels and myocardial stiffness of LV end-diastolic pressure or of a lung to body weight constant of the left ventricle and a decrease in collagen ratio (Table 1) . At 20 weeks, the increases in LV mass solubility, and tau was prolonged (Figs. 3 and 4 , Table 1 ).
index and LV mass were attenuated to a similar degree and tau was normalized in the rats treated with the angiotensin constant of the left ventricle and the decrease in collagen II type 1 receptor antagonist and in those treated with the solubility; however, the calcineurin inhibitor failed (Figs. 3 calcineurin inhibitor ( Fig. 2 and Table 1 ). The blockade of and 4). angiotensin II type 1 receptor inhibited the increase in the total tissue hydroxyproline content, the ratio of type I to type III collagen mRNA levels and myocardial stiffness 4 . Discussion
.1. Determinant of myocardial stiffness
Our previous studies demonstrated using the Dahl-S rats of diastolic heart failure model that the transition from the compensatory stage to the overt heart failure was associated with the progression of LV hypertrophy, fibrosis and myocardial stiffening, but not with the progression of LV relaxation abnormality [7, 8, 15] . Those results suggest a crucial role of myocardial stiffening in the development of heart failure. In view of the contribution of LV hypertrophy and fibrosis to myocardial stiffening, previous studies resulted in different conclusions. Narayan [9] and Matsubara [10] concluded that collagen accumulation, not LV hypertrophy, was responsible for myocardial stiffening. Schraeger et al. showed that LV hypertrophy, not fibrosis, is closely related to myocardial stiffening [11] . Our recent study reported that LV hypertrophy consists of at least two types in pressure overloaded heart [12] . One occurs in the sary and excessive for the compensation and is dependent on renin-angiotensin system. The previous studies have tent but decreased LV mass and myocardial stiffness [11] . not examined the effects of different types of hypertrophy However, a ratio of collagen I to collagen III or collagen on myocardial stiffness.
cross-linking was not assessed in that study, and the The angiotensin II type 1 receptor blockade allowed the treatment-induced decrease in myocardial stiffness might development of compensatory hypertrophy but inhibited be provided by their alteration rather than by the regression the excessive hypertrophy and fibrosis, leading to the of LV hypertrophy. normalization of myocardial stiffness constant. In our One may raise a question why the administration of recent study, myocardial stiffness constant was not incalcineurin inhibitor prevented the transition to overt creased at the compensatory hypertrophic stage [8] . Thus, diastolic heart failure without the attenuation of myocardial compensatory hypertrophy independent of renin-angiotenstiffening. Our previous study demonstrated that the prosin system is unlikely to contribute to myocardial stiffengression of LV relaxation abnormality was not observed in ing.
the transition from the compensatory stage to the heart Inhibition of calcineurin activity slowed the developfailure stage [7] . However, this does not suggest the lack ment of LV hypertrophy from an earlier stage (Fig. 2) , and of the contribution of relaxation abnormality to the onset LV mass and LV mass index reached the same level at 20 of overt heart failure, but only indicates that myocardial weeks as in the rats treated with angiotensin II type 1 stiffening triggers the deleterious cardiac disorder in the receptor antagonist. This indicates that the calcineurin presence of relaxation abnormality. Thus, the attenuation inhibition allowed the development of compensatory hyof LV relaxation abnormality by inhibiting calcineurin pertrophy alone, but not of the excessive hypertrophy.
activity may have prevented the transition to overt diastolic However, the administration of calcineurin inhibitor failed failure. Second, LV end-diastolic pressure was considerably to decrease myocardial stiffness constant and did not lowered in the rats treated with calcineurin inhibitor attenuate LV fibrosis. Thus, the excessive LV hypertrophy compared with the untreated rats despite a small difference as well as compensatory hypertrophy is not responsible for in LV end-diastolic dimension, suggesting lowered LV myocardial stiffening, but LV fibrosis is responsible .
chamber stiffness in the treated rats. Myocardial stiffness Connective tissue accumulation has been considered as a is only one of the determinants of chamber stiffness, and major determinant of tissue stiffness. Recently, an interest the inhibition of the excessive hypertrophy should have in collagen functional structure as well as total collagen contributed to the attenuation of chamber stiffening, leadcontent has been growing. Tissue with predominant coling to the prevention of overt diastolic failure. lagen I is characterized by strength and stiffness, whereas tissues containing large amounts of collagen III are char-4 .2. Study limitations acterized by an increased elasticity. Enhanced collagen cross-linking is likely to decrease tissue distensibility. In
There are several limitations in this study. First, the the current study, the angiotensin II type 1 receptor compensatory hypertrophy that developed under the anblockade, but not the calcineurin inhibition, normalized a giotensin II type 1 receptor blockade and the calcineurin ratio of collagen I to collagen III and collagen solubility inhibition may not have similar characteristics. There is a (an index of collagen cross-linking) in association with the possibility that the compensatory hypertrophy allowed by attenuation of collagen accumulation. Our previous study the administration of calcineurin inhibitor is responsible showed that a ratio of collagen I to collagen III, rather than for the increased myocardial stiffness rather than LV total collagen content, is an important determinant of fibrosis. The present and previous in vivo studies have myocardial stiffness in the Dahl-S rats, the same model as reached the conclusions assuming that effects of LV in the current study [20] . Norton et al. reported that hypertrophy are related to LV weight. To confirm whether myocardial stiffness is attributed to alteration in collagen this assumption is correct or not, further study is necessary. cross-linking in spontaneously hypertensive rats [24] . As Second, several studies have suggested that functional the collagen phenotype and the collagen cross-linking as structure, i.e. collagen phenotype and cross-linking of well as the collagen content changed in parallel with collagen, influences on myocardial stiffness [20, [24] [25] [26] . In myocardial stiffness constant in this study, the current this study, they changed with total collagen content, and it results at least suggest that not only collagen content but was difficult to clarify their independent importance in also functional structure of collagen network plays an determining myocardial stiffness in this hypertensive diasimportant role in determining myocardial stiffness. tolic heart failure model. A reason why the previous studies [9] [10] [11] reached different conclusions about determinants of myocardial 4 .3. Conclusions stiffness may be partly explained by taking account of the roles of the collagen functional network. Schraeger et al.
Myocardial stiffening is enhanced by progressive colconcluded that fibrosis did not influence myocardial stifflagen accumulation, collagen phenotype shift and enness by demonstrating that the treatment with captopril and hanced collagen cross-linking, but not by compensatory or hydrochlorothiazide did not decrease hydroxyproline conexcessive LV hypertrophy in hypertensive hearts.
